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Abstract
Background Expression of estrogen receptor alpha (ERα)
is predictive for endocrine therapy response and an
important prognostic factor in breast cancer. Overexpres-
sion of ERα can be caused by estrogen receptor 1 (ESR1)
gene amplification and was originally reported to be a
frequent event associated with a significantly longer
survival for ER-positive women treated with adjuvant
tamoxifen monotherapy, which was however questioned
by subsequent studies.
Methods This study aimed to reanalyze the frequency of
ESR1 amplification by multiplex ligation-dependent probe
amplification (MLPA) and fluorescence in situ hybrid-
isation (FISH), and to assess clinicopathologic correlations.
MLPA was performed in a group of 135 breast cancer
patients, and gains/amplifications were subjected to FISH.
Results True ESR1 amplification by MLPA was rare (2%)
and only 6% more patients showed a modest gain of ESR1.
All MLPA-detected ESR1 amplifications and nearly all
ESR1 gains were also FISH amplified and gained, but not
all FISH amplifications/gains were MLPA amplified/
gained, leading to an overall concordance of only 60%
between both techniques. All 3 MLPA and FISH ESR1
amplified cases had high ERα expression, but there was no
obvious correlation between ESR1 gain and ER status by
IHC. ESR1 gains/amplifications were not associated with
HER2 gain/amplification, but seemed to be associated with
older age. Surprisingly, ESR1 gain/amplification was not
associated with low grade as reported previously, but
correlated with high grade and high proliferation. Further-
more, ESR1 gain/amplification by MLPA was not associ-
ated with nodal status or tumor size (pT status).
Conclusions ESR1 amplification as detected by MLPA is
rare in breast cancer, and seems to be associated with high
ERα expression, high age, high grade and high prolifera-
tion. This study confirms previous studies that showed




The choice of therapy for breast cancer is based on clinico-
pathological features such as estrogen receptor (ERα) and
progesterone receptor (PR) status, HER2 (human epidermal
growth factor receptor 2) status, tumor size and grade.
Expression of ERα is predictive for endocrine therapy
response and an important prognostic factor for breast
cancer [1]. ERα is a member of the nuclear hormone-
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ESR1 (estrogen receptor 1), is located on chromosome
6q25 [2]. ERα regulates the transcription of many genes
(approximately 5% of the genome) by binding to estrogen
responsive elements (ERE) thereby leading to e.g. cell
proliferation. Estrogen and ERα are involved in sexual
development and reproductive function, but in pathological
situations elevated levels of ERα are seen. Ductal carcino-
ma in situ of the breast generally expressess ERα, and more
than two-thirds of invasive breast cancers are ERα positive
[3]. Several endocrine therapies targeting ERα have
successfully been developed, leading to a substantial
decrease in tumor growth in about 30–50% of ERα
expressing patients [4]. Tamoxifen is a selective estrogen
receptor modulator (SERM) and is the standard endocrine
therapy for ER-positive breast cancers [4]. It competes with
estrogen for binding to ERα and thereby inhibits gene
transcription activation and thus cell growth. Other endo-
crine therapies that are increasingly used in breast cancer
treatment are aromatase inhibitors (AIs), which block the
synthesis of estrogen [5] and fulvestrant, an estrogen-
receptor destabilizator and downregulator (SERD) [6].
Overexpression of ERα can be caused by ESR1
amplification and ESR1 amplification by fluorescence in
situ hybridization (FISH) was originally reported to be a
relatively frequent event in breast cancer, associated with a
significantly longer survival for patients treated with
adjuvant tamoxifen monotherapy [7]. Amplification of
ESR1 has subsequently been studied by several other
groups that have questioned the frequency of ERα
amplification in breast cancer patients [8]. ERα gene
amplification detection using FISH provided a frequency
of 20.6% [7] and 22.6% [9], whereas aCGH, CISH and
qPCR provided a frequency of 0–10% [10–13]. Differences
in amplification frequencies were assigned to missing the
amplification due to the small amplicon (600 kb) and the
lower levels of amplification, to tumor heterogeneity and to
contamination by normal cells. The latter two would lead to
an underestimation of the amplification frequency detected
by non-morphological techniques. Other confounding fac-
tors might be the different interpretation of the definition
‘amplification’ and/or the use of an automated/manual
scoring system for ISH [8].
Multiplex ligation-dependent probe amplification
(MLPA) is a molecular technique to detect gene copy
number changes, that, for HER2, has been shown to
correlate well with immunohistochemistry (IHC), fluores-
cence in situ hybridization (FISH) and chromogenic in situ
hybridization (CISH) [14]. MLPA is a PCR-based method
for gene copy number quantification in DNA extracted
from frozen or paraffin embedded tissue. MLPA kits
contain up to 45 probes which can be simultaneously
detected in one PCR reaction [15, 16]. This study aimed to
analyze the frequency of ESR1 amplification by MLPA in a
large group of breast cancer patients and to compare ESR1
gains and amplifications detected by MLPA with FISH and
clinicopathologic features. This study will show that ESR1
amplification detected by MLPA is rare in breast cancer,
and seems to be associated with high ERα expression, high
age, high grade and high proliferation.
2 Materials and methods
2.1 Patient material
Tissue samples of invasive breast cancer patients were
collected between November 2004 and September 2009 at
the Department of Pathology of the University Medical
Centre in Utrecht (UMCU), The Netherlands. This study
randomly selected 135 tissue samples from this consecutive
series. According to the Dutch Federation of Medical
Scientific Societies (the FEDERA), use of redundant tissue
for research purposes does not require informed consent, if
the patients are offered the possibilities to refuse this
(“opting out” system) and material has been used anony-
mously or coded. In the UMC Utrecht, all patients are
informed that research may happen with their redundant
tissue, and are offered to opt out [17]. No material of
patients that have opted out has been used in the present
study, and all materials were used anonymously. The
research protocol for this study was approved by the
Scientific Advisory Counsel of the UMC Utrecht Biobank.
Grading was performed according to the Nottingham
modification of Bloom-Richardson system, and mitoses
were counted according to a strict protocol as before to
arrive at the mitotic activity index (MAI) [18]. All tissue
samples were analyzed with MLPA to determine ESR1 and
HER2 gene copy number alternations. Furthermore, HER2,
ER and PR protein expression were assessed by immuno-
histochemistry, and histological type, tumor size, histolog-
ical grade and age at diagnosis were determined for all
patients. Tumors showing ESR1 gain or amplification by
MLPA were re-analyzed by FISH, as were 14 tumors with
normal MLPA ESR1 results. For all FISH-analyzed tumors
in this study, HER2 CISH data were already available from
previous studies [14, 19].
2.2 Immunohistochemistry
IHC for HER2 was performed using the Hercep test (Dako,
Glostrup, Denmark) according to the manufacturers’ instruc-
tions on 4 μm thick sections from the neutral buffered
formaldehyde fixed tissue blocks. IHC membrane staining
was semi-quantitatively scored as negative (0), weakly
positive (1+), equivocal (2+) and strongly positive (3+)
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Interpretation of staining was done by 2 experienced breast
pathologists.Ascontrolasmalltissuearraycontaininga0,1+,
2+ and 3+ breast tumor samples was taken along on the same
slide as the tumor to be analyzed. Immunohistochemical
staining for ER (1D5, 1:80, Dako) and PR (PGR636, 1:200,
Dako) was performed using a Bond-Max automated staining
machine (Vision Biosystems, Newcastle, UK) with the Bond
polymer refine detection kit (Vision BioSystems, cat. no
DS9800). Appropriate positive and negative controls were
used throughout.
2.3 Multiplex ligation-dependent probe amplification
(MLPA)
Invasive tumor areas as identified on serial H&E sections
were harvested from one or two whole 4 μm thick paraffin
sections (corresponding to approximately 1 square cm of
tumor tissue) with a scalpel. DNA was isolated from these
tissue fragments by 1 hr incubation in proteinase K (10 mg/
ml; Roche, Almere, The Netherlands) and lysis buffer
(50 mM Tris-HCl buffer pH 8.0 with 0.5% Tween 20) at
56°C followed by boiling for 10 min. This DNA solution
(50–100 μl) was, after centrifugation, used in the MLPA
analysis according the manufacturers’ instructions, using
the P004-B1 kit (MRC Holland, Amsterdam, The Nether-
lands). This kit contains, amongst others, two probes for
ESR1 and three for HER2. All tests were performed in
duplicate in an ABI 9700 PCR machine (Applied Bio-
systems, Foster City, CA, USA). PCR products were
analyzed on an ABI310 capillary sequencer (Applied
Biosystems). Gene copy numbers were analyzed using
Genescan (Applied Biosystems) and Coffalyser (version
9.4) software (MRC-Holland). For genes with more than
one probe present in the kit, the mean of all the probe peaks
of this gene in duplicate was calculated. If this mean value
was below 0.7 the respective gene was defined as lost, a
value between 0.7–1.3 was defined as normal, 1.3–2.0 as
gain, and values >2.0 as amplified, as previously estab-
lished [20, 21].
2.4 FISH
FISH was performed using the ZytoLight®SPEC ESR1/
CEN 6 Dual Color Probe kit (Zytovision, Germany, Z-
2070-20) according to the manufacturer’s instructions.
Briefly, slides were deparaffinised and incubated for
15 min in Heat Pretreatment Solution Citric at 98°C. Slides
were incubated in a pepsin solution for 10 min at 37º C,
washed in Wash buffer SSC, dehydrated and air dried.
Subsequently, 10 μl of ZytoLight®SPEC ESR1/CEN 6
Dual Color Probe was applied to the slides followed by
denaturation at 75°C for 10 min and incubation overnight at
37°C in a Thermobrite StatSpin system (Abbott Molecular).
After hybridization, coverslips were removed in Wash
Buffer A at 37°C for 2 min, followed by a wash in the
same Wash Buffer for 2× 5 min at 37°C, dehydration and
DAPI/antifade solution for 15 min in the dark. Evaluation
of the sample was carried out using a Leica DM5500 B
fluorescence microscope (Leica Microsystems, Germany)
and Leica AF6000 software. The ESR1 probe was labelled
with ZyGreen (green, excitation at 503 nm and emission at
528 nm) and the CEP6 alpha-satellite probe with ZyOrange
(orange, excitation at 547 nm and emission at 572 nm).
Interpretation of the results was based on the counting of at
least 30 tumor cells in at least two different areas by one
blinded observer, and we used two different approaches: the
ESR1 absolute copy number and the ESR1/CEP6 ratio. A
sample was defined as gained if the absolute ESR1 copy
number was >2 or the ESR1/CEP6 ratio was >1.0, and as
amplified if the absolute ESR1 copy number was >10 or if
the ESR1/CEP6 ratio was >2.2.
3 Results
3.1 MLPA
Of the 135 tumors analyzed by MLPA, 2% showed ESR1
amplification (3/135) and 6% showed ESR1 gain (8/135).
Fifteen percent of the patients showed HER2 amplification
(20/135) by MLPA, and 5% more showed HER2 gain (7/
135). None of the 3 true ESR1 amplifications were
associated with HER2 amplification, but 4/8 ESR1 gains
were associated with HER2 gain (2/4) or HER2 amplifica-
tion (2/4). There were no losses of ESR1 by MLPA in this
study, although 10 tumors had copy number ratios in the
lower range between 0.7 and 0.8.
3.2 FISH
Supplementary Table 1 shows the association between
ESR1 copy number status by MLPA and ESR1 status by
FISH (separated into the ESR1/CEP6 ratio and the ESR1
absolute copy number). Figure 1 and Tables 1 and 2 show
that all three amplifications by MLPA were also amplified
by FISH using both FISH interpretation methods. Table 1
shows that four of the 8 MLPA-detected ESR1 gains were
also FISH amplified, 2/8 were FISH gained and 2/8 were
not amplified by FISH using the ratio interpretation. Of all
25 FISH-analyzed samples, 13/25 (52%) showed an
increased (>2) CEP6 copy number.
Using the absolute copy number interpretation as shown
in Table 2, 3/8 MLPA-detected gains were also FISH
amplified, 4/8 were FISH gained and 1/8 MLPA gains was
not amplified by FISH.
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by FISH of which 10/14 were normal, 1/14 was gained and 3/
14 were amplified by FISH using the ratio interpretation.
Using the absolute copy number interpretation, 6/14 MLPA
non-amplified tumors showed no amplification by FISH, 7/14
were gained and 1/14 was amplified by FISH. This study
found two ESR1 losses by FISH which were both associated
with lower MLPA copy number ratios (0.72 and 0.73).
3.3 Association with clinicopathological features
Supplementary Table 1 shows that all three MLPA-detected
ESR1 amplifications were associated with 100% ER posi-
tivity. Of the eight ESR1 gains by MLPA, 5 had very high
ER expression (90–100%) and 3 were ER negative. Two of
the 3 tumors with ESR1 amplifications were grade 3 and 1
was grade 1. All 8 tumors with ESR1 gains were non-low
grade (5/8 grade 3, 3/8 grade 2) and, in total, 24/25 grade 1
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amplifications and eight ESR1 gains, 2/3 and 6/8 had high
MAI (>10), respectively. All but one (lobular) tumors with
ESR1 amplifications or gains were of the ductal type. All
patients with ESR1 gain/amplification by MLPA were older
than 50 years. Two of the three MLPA-detected amplifica-
tions were pT1, the other was pT2. Six of the 8 ESR1 gains
were pT1 (<2 cm), whereas 2/8 were pT2. The lymph node
status of the 3 patients with MLPA-detected amplifications
was pN0 in 2/3, and pN1 in 1/3. For the MLPA-detected
gains, 5/8 were pN0 and 3/8 pN1.
Table 1 shows 10 ESR1 FISH amplifications and 3 gains
using the ESR1/CEP6 ratio for interpretation. All 10 FISH
amplifications had high ER expression (90–100%) but 2/3
gains were completely ER negative. None of the ESR1
FISH amplified tumors were HER2 CISH amplified, but all
3 FISH-detected gains were HER2 CISH amplified. Nine of
the 10 FISH amplifications were non-low grade (7/9 grade
3, 2/9 grade 2). All but two of these ESR1 FISH
amplifications were also associated with high MAI. Five
and 6 of the 10 ESR1 FISH amplifications were pN0 and
pT1 respectively. The other five and 4 ESR1 amplifications
were pN1 and pT2, respectively. Two patients with ESR1
FISH amplification were younger than 50. All three gains
were non-low grade (1/3 grade 3, 2/3 grade 2), had a high
MAI, were pN0, pT1 and older than 50.
Using the absolute ESR1 copy number for interpretation,
all 7 FISH amplifications had high ER expression (90–100%)
butonly5/11FISHgainswereERpositive.NoneoftheESR1
FISH amplified tumors were HER2 CISH amplified, but 3/11
FISH-detected gains were HER2 CISH amplified. Five of the
seven amplifications were non-low grade (4/5 grade 3 and 1/5
grade 2), and all but two of the amplifications were associated
withhighMAI. Of the 7 amplifications, 4/7 were pN0 and 3/7
pN1, 3/7 were pT1 and 4/7 pT2. All 7 patients with ESR1
amplifications were older than 50 years of age. All but one of
Fig. 1 ESR1 (green) amplification by FISH in 3 multiplex ligation-dependent probe amplification (MLPA)-amplified patients. CEP6 is indicated
in red
Table 2 Concordance between ESR1 MLPA ratio and FISH absolute
ESR1 copy number
FISH ESR1 absolute copy Total
NA G A
MLPA NA 6 7 1 14
G1 4 3 8
A0 0 3 3
Total 7 11 7 25
Amplification (A), gain (G), no amplification (NA)
Table 1 Concordance between ESR1 MLPA ratio and FISH ESR1/
CEP6 ratio
FISH ESR1/CEP6 ratio Total
NA G A
MLPA NA 10 1 3 14
G2 2 4 8
A0 0 3 3
Total 12 3 10 25
Amplification (A), gain (G), no amplification (NA)
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and3/10grade2)and9/11wereassociatedwithhighMAI.Of
the 11detectedESR1gains,5/11werepN0,4werepN1and2
were pN2. Seven of these 11 gains were associated with pT1,
3/11 with pT2 and 1/11 was pT3. Five of the 11 patients with
FISH-detected ESR1 gains were younger than 50.
4 Discussion
The aim of this study was to analyze the frequency of ESR1
amplification by MLPA, to confirm these amplifications by
FISH, and to associate these amplifications with clinico-
pathological features. ESR1 amplification by MLPA was
rare (2%) and additionally 6% of the patients showed ESR1
gain. All MLPA-detected ESR1 amplifications and nearly
all ESR1 gains were also FISH amplified and gained, but
not all FISH amplifications/gains were MLPA amplified/
gained, with a 60% overall concordance (15/25) between
MLPA and FISH using the ratio interpretation method and a
52% concordance (13/25) between MLPA and FISH using
the absolute ESR1 copy number. Although the ESR1/
CEP17 FISH ratio showed a slightly better correlation with
MLPA than the absolute FISH ESR1 copy number, there
was overall not a very good concordance between MLPA
and FISH. FISH seemed to detect more amplifications than
MLPA (in this selected group 40% (10/25) plus 12% (3/25)
gains). Our percentage of ESR1 amplification by MLPA
was much lower than the 20.6% found by Holst et al. [7]
using BAC FISH on tissue microarrays, but was consistent
with the lower range (0–10%) of ESR1 amplification
reported by other groups using a broad range of techniques
such as array comparative genomic hybridization (aCGH),
CISH, FISH and qPCR [8–13, 22]. Several reasons have
been postulated for the difference in amplification frequen-
cies reported by these techniques including heterogeneity or
contamination by normal DNA (aCGH, qPCR, MLPA in
this study—although we microdissected the tumor area),
the small ESR1 amplicon size (although HER2 also has a
small amplicon size: 500–700 kb), low levels of amplifica-
tion (only 15% of its amplifications were >10 copies, 41%
5–6 copies), large CISH probes (360 kb), and an automat-
ed/manual scoring system. According to Holst et al. [22],
detection of ESR1 amplification by FISH will require
modifications of the established procedures.
Given the low amount of ESR1 gains and amplifications
in this study, it was not deemed appropriate to perform
statistical analysis. Therefore, for the association with
clinicopathological parameters, frequencies were used
rather than statistical p-values. ESR1 gain/amplification
was not associated with low grade as reported by Holst et
al. [7], but in contrary, seemed to be associated with higher
grade (2 or 3) and high MAI. This could however explain
in part the observation of Ejlertsen et al. that patients with
ESR1 amplification treated with tamoxifen had a shorter
time to recurrence [23] and the fact that Lyng et al. [24]
found ESR1 amplification more frequently in patients with
recurrence (6/7 amplified patients showed recurrence in
contrast to 22/46 patients without ESR1 amplification)
upon tamoxifen treatment. We did not find an obvious
relation between ESR1 gain/amplification and tumor size
(pT status) or lymph node status (pN status), but ESR1
gains/amplifications seemed to be associated with higher
age.
Similar to Holst et al., all ESR1 amplifications detected
by MLPA or FISH were 90–100% ERα positive. For ESR1
gains, there was no obvious correlation with ERα protein
overexpression.
5 Conclusion
In conclusion, this study used MLPA to detect ESR1
amplification in a group of 135 patients and detected
only 2% amplification and 6% more gains. All ESR1
amplifications by MLPA or FISH had high ERα
expression by IHC, but for ESR1 gains this was not
obvious. ESR1 gains/amplifications were not associated
with HER2 gain/amplification. Surprisingly, ESR1 gain/
amplification was not preferably associated with low-
grade tumors as reported previously, but in contrast
seemed to be associated with high grade and high
MAI. ESR1 amplification by MLPA was associated with
higher age, but not with nodal status or pT status. All
MLPA-detected ESR1 amplifications and nearly all ESR1
gains were also FISH amplified and gained, but not all
FISH amplifications/gains were MLPA amplified/gained,
leading to an overall concordance of only 60% between
both techniques. This confirms previous studies that
showed differences in the amplification frequencies
detected by different techniques.
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